Cadrenal therapeutics and abbott initiate collaborative effort to advance novel anticoagulant tecarfarin for patients with lvads

Ponte vedra, fla., aug. 6, 2024 /prnewswire/ -- cadrenal therapeutics, inc., (nasdaq: cvkd), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation vitamin k antagonist (vka) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it has been in discussions with abbott (nyse: abt) about cadrenal's planned pivotal study of tecarfarin in patients with recently implanted lvads.
ABT Ratings Summary
ABT Quant Ranking